Literature DB >> 16376294

Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A2 surfactant hydrolysis.

R Duncan Hite1, Michael C Seeds, Randy B Jacinto, Bonnie L Grier, B Moseley Waite, David A Bass.   

Abstract

Secretory A(2) phospholipases (sPLA(2)) hydrolyze surfactant phospholipids cause surfactant dysfunction and are elevated in lung inflammation. Phospholipase-mediated surfactant hydrolysis may disrupt surfactant function by generation of lysophospholipids and free fatty acids and/or depletion of native phospholipids. In this study, we quantitatively assessed multiple mechanisms of sPLA(2)-mediated surfactant dysfunction using non-enzymatic models including supplementation of surfactants with exogenous lysophospholipids and free fatty acids. Our data demonstrated lysophospholipids at levels >or=10 mol% of total phospholipid (i.e., >or=10% hydrolysis) led to a significant increase in minimum surface tension and increased the time to achieve a normal minimum surface tension. Lysophospholipid inhibition of surfactant function was independent of the lysophospholipid head group or total phospholipid concentration. Free fatty acids (palmitic acid, oleic acid) alone had little effect on minimum surface tension, but did increase the maximum surface tension and the time to achieve normal minimum surface tension. The combined effect of equimolar free fatty acids and lysophospholipids was not different from the effect of lysophospholipids alone for any measurement of surfactant function. Surfactant proteins did not change the percent lysophospholipids required to increase minimum surface tension. As a mechanism that causes surfactant dysfunction, depletion of native phospholipids required much greater change (equivalent to >80% hydrolysis) than generation of lysophospholipids. In summary, generation of lysophospholipids is the principal mechanism of phospholipase-mediated surfactant injury in our non-enzymatic models. These models and findings will assist in understanding more complex in vitro and in vivo studies of phospholipase-mediated surfactant injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376294     DOI: 10.1016/j.bbamem.2005.10.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

Review 1.  Meconium-induced inflammation and surfactant inactivation: specifics of molecular mechanisms.

Authors:  Jana Kopincova; Andrea Calkovska
Journal:  Pediatr Res       Date:  2015-12-17       Impact factor: 3.756

Review 2.  Therapeutic use of surfactant components in allergic asthma.

Authors:  Veit J Erpenbeck; Norbert Krug; Jens M Hohlfeld
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-15       Impact factor: 3.000

Review 3.  Multiple roles of phospholipase A2 during lung infection and inflammation.

Authors:  Bryan P Hurley; Beth A McCormick
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

Review 4.  Function of secreted phospholipase A2 group-X in asthma and allergic disease.

Authors:  James D Nolin; Ryan C Murphy; Michael H Gelb; William A Altemeier; William R Henderson; Teal S Hallstrand
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-12-05       Impact factor: 4.698

5.  Secretory phospholipase A2-mediated depletion of phosphatidylglycerol in early acute respiratory distress syndrome.

Authors:  Michael C Seeds; Bonnie L Grier; Bruce N Suckling; Anca M Safta; David L Long; B Moseley Waite; Peter E Morris; R Duncan Hite
Journal:  Am J Med Sci       Date:  2012-06       Impact factor: 2.378

6.  Sulforhodamine B and exogenous surfactant effects on alveolar surface tension under acute respiratory distress syndrome conditions.

Authors:  Tam L Nguyen; Carrie E Perlman
Journal:  J Appl Physiol (1985)       Date:  2020-09-24

7.  Surfactant Dysfunction in ARDS and Bronchiolitis is Repaired with Cyclodextrins.

Authors:  Mustafa Al-Saiedy; Lasantha Gunasekara; Francis Green; Ryan Pratt; Andrea Chiu; Ailian Yang; John Dennis; Cora Pieron; Candice Bjornson; Brent Winston; Matthias Amrein
Journal:  Mil Med       Date:  2018-03-01       Impact factor: 1.437

8.  Postexposure Liponucleotide Prophylaxis and Treatment Attenuates Acute Respiratory Distress Syndrome in Influenza-infected Mice.

Authors:  Lucia E Rosas; Lauren M Doolittle; Lisa M Joseph; Hasan El-Musa; Michael V Novotny; Judy M Hickman-Davis; R Duncan Hite; Ian C Davis
Journal:  Am J Respir Cell Mol Biol       Date:  2021-06       Impact factor: 6.914

Review 9.  Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome--where do we go from here?

Authors:  Ahilanandan Dushianthan; Rebecca Cusack; Victoria Goss; Anthony D Postle; Mike P W Grocott
Journal:  Crit Care       Date:  2012-11-22       Impact factor: 9.097

Review 10.  The involvement of phospholipases A2 in asthma and chronic obstructive pulmonary disease.

Authors:  Ewa Pniewska; Rafal Pawliczak
Journal:  Mediators Inflamm       Date:  2013-05-13       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.